Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FDMT vs CGEM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEM Captures Overall Composite Edge (48.4 HOLD vs 42.1 HOLD), While FDMT Leads 3–2 on Growth & Valuation Pillars

CGEM Overall Winner 6-Pillar Tally: FDMT 3 – 2 CGEM (1 Tie) Matrix Metrics: FDMT 4 – 6 CGEM

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (48.4/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus CGEM at $9.72 (6.7x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CGEM earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. FDMT 42.1/100 HOLD) and 1.56β · 104% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CGEM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FDMT vs CGEM
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $12.12 · SMA50: $13.08
CGEM NASDAQ Head-to-Head Winner
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.72
-5.45% 1D
Market Cap $653.8M
TTM Revenue N/A
Forward P/E 6.7x
Beta / 30D Vol 1.56β · 104% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 45.0 Fund 51.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 30
RSI-14: 29.8 · SMA20: $13.22 · SMA50: $15.63

6-Pillar Scorecard Institutional Category Breakdown (FDMT 3 – 2 CGEM)

Columns: Metric · FDMT · CGEM
1. Valuation Multiples CGEM
Forward P/E N/M 6.7x
Trailing P/E N/M 6.7x
PEG Ratio N/M N/M
EV / Revenue 6.6x N/M
2. Growth & Scale FDMT
Revenue Growth (YoY) +4505.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $96M N/A
Market Cap $669.3M $653.8M
3. Profitability & Quality CGEM
Gross Margin N/A N/A
Operating Margin -222.7% 0.0%
Net Profit Margin -208.6% 0.0%
Return on Equity (ROE) -56.7% -50.3%
4. Balance Sheet & Cash Flow FDMT
Cash Generation (TTM) -$156M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Cash $4.33 Book/Sh · -50.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FDMT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 82.4% (10th %ile) 124.5% (9th %ile)
Put/Call OI Skew 5.16x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FDMT (4) vs CGEM (6)
Institutional Metric FDMT CGEM Criterion Row Edge
Market Capitalization
Scale
$669.3M $653.8M Larger Scale FDMT
Trailing P/E Ratio
Valuation
N/M 6.7x Lower Multiple CGEM
Forward P/E Ratio
Valuation
N/M 6.7x Lower Multiple CGEM
Revenue Growth (YoY)
Growth
+4505.6% +0.0% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-222.7% 0.0% Higher Margin CGEM
Net Profit Margin
Profitability
-208.6% 0.0% Higher Margin CGEM
Return on Equity (ROE)
Capital Efficiency
-56.7% -50.3% Higher ROE CGEM
52-Week Range Position
Momentum
47% ($7–$17) 12% ($8–$23) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.89β · 90% Vol 1.56β · 104% Vol Lower Realized Risk FDMT
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite CGEM
Trailing 12M Revenue (USD)
Operating Scale
$96M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$156M ($31M Net Cash) N/A ($4.33 Book/Sh · -50.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +20.79 pp
FDMT: -4.04% · CGEM: -24.83%
3M Horizon FDMT +32.5 pp
FDMT: -20.86% · CGEM: -53.36%
6M Horizon FDMT +73.9 pp
FDMT: +39.27% · CGEM: -34.63%
1Y Horizon CGEM +4.2 pp
FDMT: +13.33% · CGEM: +17.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FDMT vs CGEM. Trailing 12-month operating profitability (FDMT -222.7% vs CGEM 0.0%) and valuation multiples (FDMT N/M vs CGEM 6.7x Forward P/E) are benchmarked directly in Pillar 4 below.

FDMT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$96M
Gross MarginN/A
Op. Margin-222.7%
ROE / Fwd P/E-56.7% · N/M
CGEM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-50.3% · 6.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CGEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGEM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $653.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FDMT vs CGEM Key Questions & Quantitative Answers

As of Nov 16, 2026, Cullinan Therapeutics, Inc. (CGEM) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (48.4/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 6–4 (led by Valuation Multiples, Profitability & Quality), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus CGEM at $9.72 (6.7x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CGEM earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. FDMT 42.1/100 HOLD) and 1.56β · 104% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile CGEM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with CGEM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FDMT generates $96M in USD-normalized revenue versus N/A for CGEM. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGEM.

CGEM screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas CGEM trades at 6.7x Forward P/E, 6.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus CGEM (-50.3% ROE) capital efficiency.

In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, CGEM carries 124.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.56β · 104% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.